Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Alnylam Pharmaceuticals : to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference

share with twitter share with LinkedIn share with facebook
09/28/2020 | 04:01pm EDT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 4:15 pm ET via webcast.

A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), approved in the U.S., EU, Canada, Japan, Switzerland and Brazil, and GIVLAARI® (givosiran), approved in the U.S., EU, and Brazil. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about ALNYLAM PHARMACEUTICALS, INC.
10/23ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Third Quarter 20..
AQ
10/23ALNYLAM PHARMACEUTICALS : Presents Positive Results from ILLUMINATE-B Phase 3 st..
AQ
10/22ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Third Quarter 20..
BU
10/22ALNYLAM PHARMACEUTICALS : Presents Positive Results from ILLUMINATE-B Phase 3 St..
BU
10/19ALNYLAM PHARMACEUTICALS : Receives Positive CHMP Opinion for OXLUMO for the Trea..
AQ
10/16ALNYLAM PHARMACEUTICALS : Receives Positive CHMP Opinion for OXLUMO™ (luma..
BU
10/14VIR BIOTECHNOLOGY : and Alnylam to Webcast tual Fireside Chat at H.C. Wainwright..
AQ
10/02ALNYLAM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Chan..
AQ
10/02SAGE THERAPEUTICS : Appoints Barry Greene to Board of Directors
AQ
10/01ALNYLAM PHARMACEUTICALS : Reports Positive Topline Results from ILLUMINATE-B Pha..
AQ
More news
Financials (USD)
Sales 2020 467 M - -
Net income 2020 -715 M - -
Net cash 2020 1 265 M - -
P/E ratio 2020 -21,1x
Yield 2020 -
Capitalization 15 289 M 15 289 M -
EV / Sales 2020 30,1x
EV / Sales 2021 17,1x
Nbr of Employees 1 323
Free-Float 99,2%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 163,17 $
Last Close Price 131,84 $
Spread / Highest target 70,7%
Spread / Average Target 23,8%
Spread / Lowest Target -31,7%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Yvonne L. Greenstreet President & Chief Operating Officer
Michael W. Bonney Chairman
Jeffrey Poulton Chief Financial & Accounting Officer
Akshay K. Vaishnaw President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.14.47%15 289
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830